How Investors Are Reacting To Elevance Health (ELV) Joining Antitrust Lawsuit Over Out-of-Network Payments

• In early October 2025, the American Physical Therapy Association and APTA Private Practice joined a federal antitrust lawsuit against MultiPlan (now Claritev) and major health insurers, including Elevance Health, alleging coordinated efforts to systematically underpay for out-of-network provider reimbursements.
• This legal development places Elevance Health amid heightened scrutiny as the suit accuses several industry leaders of participating in a price-fixing conspiracy impacting provider payments nationwide.
• With Elevance Health’s quality ratings recently improving, we’ll examine how involvement in the federal antitrust case could affect its investment narrative.

These 10 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

Elevance Health Investment Narrative Recap

To be a shareholder of Elevance Health, you need to see the company's efforts in analytics, AI, and broader value-based care initiatives as effective in managing cost pressures and sustaining long-term growth. The latest antitrust lawsuit may raise reputational risk and introduce new uncertainty, but it does not directly alter immediate catalysts like improved quality ratings; for now, the most pressing short-term risk remains stubbornly high medical cost trends, which can pressure margins and profitability if not mitigated.

One recent announcement that ties into these themes is Elevance Health’s improvement in Medicare Advantage star ratings, with over half its members now in plans rated four stars or higher. This matters because elevated star ratings are tied to bonus payments, directly supporting earnings and serving as a counterweight to operational risks and potential legal overhangs from cases like the federal antitrust suit.

In contrast, legal and regulatory scrutiny tied to pricing practices could complicate the path to…

Read the full narrative on Elevance Health (it's free!)

Elevance Health's outlook anticipates $230.4 billion in revenue and $7.4 billion in earnings by 2028. This implies 6.8% annual revenue growth and a $2.0 billion increase in earnings from the current $5.4 billion level.

Uncover how Elevance Health's forecasts yield a $361.39 fair value, in line with its current price.

Exploring Other Perspectives

Fourteen Simply Wall St Community members recently estimated Elevance Health’s fair value ranging from US$297 to US$1,344 per share. While projections diverge, the persistent challenge of elevated medical cost trends remains central for those watching long-term profitability and margin resilience, explore what drives your own perspective.

Explore 14 other fair value estimates on Elevance Health - why the stock might be worth over 3x more than the current price!

Build Your Own Elevance Health Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Elevance Health research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Elevance Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Elevance Health's overall financial health at a glance.

Curious About Other Options?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com